Home Page

Leverkusen, Germany, 22 May 2015 - Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing its results for the first three months period ending 31 March 2015 on 29 May 2015.
There is a conference call for shareholders and interested investors on 29 May 2015 at the following times:

9.00am CET (8.00am UK) conference call in German:
Dial-in number: +49-(0)69 271340800
Room number: 24938840#

10.00am CET (9.00am UK) conference call in English:
Dial-in number: +44 20336 45807
Room number: 52406056#

Ends

Enquiries, please contact:

Background:

The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz ^® , a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz ^® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos ^® dermatological range of cosmetics. Belixos ^® products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos ^® cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.